Download PDFPDF

Original article
Inter-individual variation in midazolam clearance in children
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Developmental influences on the pharmacokinetics and pharmacodynamics of midazolam

    I have read with great interest the systematic review to determine the extent of inter-individual variation in clearance of midazolam in children and to establish which factors are responsible for this variation (1). The authors found that the coefficient of clearance in plasma was greater in critically ill patients than non-critically ill patients. Furthermore, there is also a large inter-individual variation in midazola...

    Show More
    Conflict of Interest:
    None declared.